- Home
- LWLG vs BCYC Comparison
LWLG vs BCYC Comparison
Compare LWLG & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWLG
- BCYC
- Stock Information
- Founded
- LWLG 1991
- BCYC 2009
- Country
- LWLG United States
- BCYC United Kingdom
- Employees
- LWLG N/A
- BCYC N/A
- Industry
- LWLG Containers/Packaging
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- LWLG Industrials
- BCYC Health Care
- Exchange
- LWLG Nasdaq
- BCYC Nasdaq
- Market Cap
- LWLG 423.3M
- BCYC 492.1M
- IPO Year
- LWLG N/A
- BCYC 2019
- Fundamental
- Price
- LWLG $3.14
- BCYC $6.86
- Analyst Decision
- LWLG
- BCYC Buy
- Analyst Count
- LWLG 0
- BCYC 11
- Target Price
- LWLG N/A
- BCYC $22.91
- AVG Volume (30 Days)
- LWLG 2.5M
- BCYC 218.3K
- Earning Date
- LWLG 11-12-2025
- BCYC 10-30-2025
- Dividend Yield
- LWLG N/A
- BCYC N/A
- EPS Growth
- LWLG N/A
- BCYC N/A
- EPS
- LWLG N/A
- BCYC N/A
- Revenue
- LWLG $94,355.00
- BCYC $19,281,000.00
- Revenue This Year
- LWLG N/A
- BCYC N/A
- Revenue Next Year
- LWLG N/A
- BCYC $0.27
- P/E Ratio
- LWLG N/A
- BCYC N/A
- Revenue Growth
- LWLG 4.52
- BCYC N/A
- 52 Week Low
- LWLG $0.79
- BCYC $6.10
- 52 Week High
- LWLG $4.23
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- LWLG 58.29
- BCYC 39.00
- Support Level
- LWLG $2.98
- BCYC $6.84
- Resistance Level
- LWLG $3.50
- BCYC $7.32
- Average True Range (ATR)
- LWLG 0.44
- BCYC 0.38
- MACD
- LWLG -0.04
- BCYC 0.01
- Stochastic Oscillator
- LWLG 49.63
- BCYC 12.32
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.